Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
101. |
ECCT/16/02/05 | PfSPZ Malaria Vaccine Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age de-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy |
Principal Investigator(s) 1. Martina Oneko 2. Mary J Hamel Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Wagai Health Center (Siaya county) |
View |
102. |
ECCT/15/11/05 | FALCI Study A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya 1. KEMRI Center for Respiratory Diseases Research (Siaya county) 2. KEMRI Walter Reed Kombewa (Kisumu county) 3. KEMRI Kisumu (Kisumu county) |
View |
103. |
ECCT/15/11/04 | VAC040 A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months) |
Principal Investigator(s) 1. John Anthony Gerard Scott Site(s) in Kenya KEMRI-Wellcome Trust Research Program |
View |
104. |
ECCT/15/06/04 | A5316 A5316 Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy |
Principal Investigator(s) 1. Dr. Esther Mumbi Makanga Makanga 2. Dr. Victor Akelo Akelo 3. Dr.Victor O. Mudhune Mudhune 4. Dr. Kevin P. Cain Cain Site(s) in Kenya KEMRI- CDC |
View |
105. |
ECCT/15/05/01 | Janssen Ebola vaccine study A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa |
Principal Investigator(s) 1. Prof Omu Aggrey Anzala Site(s) in Kenya KAVI –Institute of Clinical Research |
View |